Key result
Midlife hypertension links to higher Alzheimer's risk, while antihypertensive therapy shows weak benefit.
Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: The relationship between hypertension and Alzheimer's disease (AD) is complex and varies across the lifespan. Studies have suggested that midlife hypertension is a risk factor for AD, although studies of late life hypertension have suggested that it either has no effect or a weak protective effect. RECENT FINDINGS: Animal models of induced and spontaneous hypertension have found that AD pathological change (β-amyloid plaques and tau tangles) occurs within weeks of a hypertensive insult. Human imaging and autopsy studies indicate that midlife and late life hypertension are associated with increased AD pathological change. Meta-analyses of longitudinal studies indicate that midlife rather than late life hypertension is a risk factor for AD. New areas of research have suggested that rather than mean blood pressure (BP), it is the negative BP trajectories or the variability of BP that contributes to AD. In a number of meta-analyses of antihypertensive medications and their effect on AD, there were weak associations between improved AD outcomes and treatment. SUMMARY: The combined analysis of animal, human clinical/pathological, epidemiological and drug trial data indicates that hypertension increases the risk of AD and treatment of hypertension may be an appropriate preventive measure.
No takes yet. Share an insight, caveat, or question.
Lennon et al. (2020) conducted a review in Hypertension and Alzheimer's disease. Hypertension and antihypertensive medications was evaluated on Alzheimer's disease risk and pathological change. Midlife hypertension increases Alzheimer's disease risk and pathology, while antihypertensive therapy shows weak associations with improved outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: